Holen Sie sich die Stockscreener-App
45.77
0.28%
-0.13
Vorhandelsmarkt:
45.47
-0.30
-0.66%
Schlusskurs vom Vortag:
$45.90
Offen:
$45.87
24-Stunden-Volumen:
2.11M
Relative Volume:
0.70
Marktkapitalisierung:
$8.69B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-18.99
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
-2.54%
1M Leistung:
+9.68%
6M Leistung:
+27.71%
1J Leistung:
+71.62%
1-Tages-Spanne:
$45.29
$46.39
1-Wochen-Bereich:
$45.29
$47.66
52-Wochen-Spanne:
$21.72
$48.68
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
45.77 | 8.92B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio Pharma Inc. Stock Analysis and ForecastConsistently profitable trades - jammulinksnews.com
Is BridgeBio Pharma Inc. a good long term investmentOutstanding risk-reward balance - jammulinksnews.com
What analysts say about BridgeBio Pharma Inc. stockRobust investment performance - jammulinksnews.com
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET - The Manila Times
BridgeBio Pharma, Inc. Scheduled to Release Q2 Financial Results and Business Updates on August 5, 2025 - Nasdaq
BridgeBio, Genetic Disease Pioneer, Sets Q2 2025 Earnings Release DateKey Details Inside - Stock Titan
What drives BridgeBio Pharma Inc. stock priceHigh-octane gains - Autocar Professional
BridgeBio Pharma Stock (BBIO) Opinions on Analyst Buy Ratings and Attruby Launch - Quiver Quantitative
BridgeBio stock initiated with Buy rating at Truist on strong Attruby launch - Investing.com Canada
BridgeBio Pharma (BBIO) Receives New 'Buy' Rating from Truist Se - GuruFocus
BridgeBio Pharma stock maintains Buy rating at H.C. Wainwright after royalty deal - Investing.com Canada
These 2 Momentum Stocks Got a Bullish Nod — Here’s Why They Could Reach New Highs - The Globe and Mail
Jefferies Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $70 - 富途牛牛
Scotiabank Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
Citi reiterates Buy rating on BridgeBio stock ahead of key trial data - Investing.com Canada
Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com
BridgeBio Pharma (BBIO) Receives Buy Rating from Jefferies | BBIO Stock News - GuruFocus
Citi Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $67 - 富途牛牛
Jefferies Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN
BridgeBio Pharma stock initiated with Buy rating at Jefferies on Attruby potential - Investing.com Canada
BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA - MSN
BridgeBio Pharma's BBP-418: A Promising Investment in Groundbreaking LGMD2I/R9 Therapy - AInvest
BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights - MSN
Helix shareholders to vote on BridgeBio Oncology merger on August 4 By Investing.com - Investing.com Nigeria
Helix shareholders to vote on BridgeBio Oncology merger on August 4 - Investing.com Australia
Cancer-Focused BridgeBio's $949M SPAC Deal Gets SEC Nod - Law360
BridgeBio Oncology's SPAC Merger Advances: SEC Clears Path for Novel Cancer Drug Development Platform - Stock Titan
BridgeBio Pharma stock hits 52-week high, reaching $45.53 By Investing.com - Investing.com South Africa
BridgeBio Pharma Inc. Rockets on Strategic Moves - StocksToTrade
BridgeBio Pharma stock hits 52-week high, reaching $45.53 - Investing.com Australia
Oppenheimer Upgrades BridgeBio Pharma to Outperform From Market Perform, Price Target is $60 - MarketScreener
BridgeBio Pharma (BBIO) Receives Rating Upgrade to Outperform | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Shares Upgraded with Positive Outlook on Future Sales | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Upgraded to Outperform with New Price Target | BBIO Stock News - GuruFocus
High Growth Tech Stocks To Watch In The US July 2025 - simplywall.st
BridgeBio Pharma’s SWOT analysis: stock poised for growth on strong pipeline - Investing.com
BridgeBio Pharma (BBIO) Opinions on $300 Million Royalty Financing Deal - Quiver Quantitative
BridgeBio Pharma Enters Royalty Purchase Agreement - TipRanks
Latham & Watkins Advises BridgeBio on US$300 Million Strategic Royalty Sale of BEYONTTRA® European Royalties - Latham & Watkins LLP
Viking Global Investors sells $154 million in BridgeBio Pharma (BBIO) By Investing.com - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Aardvark Therapeutics, Inc. (AARD), BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma director Valantine buys shares worth $30,027 - Investing.com
BridgeBio Pharma Sells Part of Beyonttra Royalty Rights for $300 Million - MarketScreener
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty | BBIO Stock News - GuruFocus
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty - The Globe and Mail
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):